Mitomycin- and calcineurin-associated HUS, endothelial dysfunction and endothelial repair: a new paradigm for the puzzle?
| Autor: | Laura Sautina, Sergey Zharikov, Ronak Shah, Elaine Beem, Mark S. Segal |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Endothelium medicine.medical_treatment Mitomycin Antigens CD34 Adenocarcinoma urologic and male genital diseases Endothelial progenitor cell Pathogenesis Renal Dialysis Stomach Neoplasms hemic and lymphatic diseases medicine Humans Renal replacement therapy Endothelial dysfunction Progenitor cell Erythropoietin Transplantation Antibiotics Antineoplastic business.industry Calcineurin medicine.disease Burkitt Lymphoma Endothelial stem cell medicine.anatomical_structure Nephrology Immunology Hemolytic-Uremic Syndrome Female Endothelium Vascular business Biomarkers |
| Zdroj: | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 22(2) |
| ISSN: | 0931-0509 |
| Popis: | Thrombotic microangiopathies (TMA) are multisystem disorders characterized by the formation of platelet-rich, fibrin-poor thrombi within the microvasculature. While there have been major advances into the cause of certain types of TMAs that have led to rational treatment choices [1], TMA secondary to chemotherapeutic and calcineurin inhibitors remains a black box both in terms of pathogenesis and treatment. Here we report a case of mitomycin-associated haemolytic uremic syndrome (HUS) resistant to conventional treatment but which responded to chronic end-stage renal disease management consisting of haemodialysis and erythropoietin treatment. We hypothesized that haemodialysis and erythropoietin may play a role in ‘healing’ the endothelial injury. To support our hypothesis, we measured the markers of endothelial cell injury (circulating endothelial cells) and a marker of endothelial repair (CD34þ endothelial progenitor cell migratory activity) in a second case of TMA secondary to calcineurin therapy. We demonstrate that, in drug-induced HUS, there is increased endothelial injury and a defective repair mechanism and that correcting uraemia, with renal replacement therapy, and treatment with specific medications aimed at enhancing endothelial repair may be able to alter the course of the disease. These findings not only suggest a mechanism for drug-induced TMA, but also suggest a rational line of therapy for a disease that heretofore was treated with supportive care. Methods |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|